Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Ruddy

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
F1000Research|October 27, 2025
Tumor-driven stromal reprogramming in the pre-metastatic lymph nodeMichelle Piquet, David A Ruddy, Viviana Cremasco, et al.
Biochemical and Biophysical Research Communications|December 12, 2018
Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancersFlorencia Rago, Matthew T DiMare, GiNell Elliott, et al.
Molecular Cancer Research : MCR|March 12, 2021
RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell ProliferationMatthew S Crowe, Tatiana Zavorotinskaya, Charles F Voliva, et al.
Cancer Discovery|February 13, 2015
FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal TumorsFang Li, Hung Huynh, Xiaoyan Li, et al.
Molecular Cancer Therapeutics|September 19, 2019
Distinct Transcriptional Programming Drive Response to MAPK Inhibition in <i>BRAF</i> <sup>V600</sup>-Mutant Melanoma Patient-Derived XenograftsTianshu Feng, Javad Golji, Ailing Li, et al.
Molecular Cancer Research : MCR|September 12, 2018
Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant MelanomaGrace P Leung, Tianshu Feng, Frederic D Sigoillot, et al.
Molecular Cancer Research : MCR|June 29, 2017
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic ActivityCaroline M Emery, Kelli-Ann Monaco, Ping Wang, et al.
The Journal of Clinical Investigation|June 18, 2024
Dysfunction of infiltrating cytotoxic CD8+ T cells within the graft promotes murine kidney allotransplant toleranceTakahiro Yokose, Edward S Szuter, Ivy Rosales, et al.
Elife|April 21, 2017
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human <i>ALK</i> mutant neuroblastoma cell lines and xenograft modelsHui Qin Wang, Ensar Halilovic, Xiaoyan Li, et al.
Cancer Research|June 24, 2011
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patientsRalph Tiedt, Elisa Degenkolbe, Pascal Furet, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
F1000Research|October 27, 2025
Tumor-driven stromal reprogramming in the pre-metastatic lymph nodeMichelle Piquet, David A Ruddy, Viviana Cremasco, et al.
Biochemical and Biophysical Research Communications|December 12, 2018
Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancersFlorencia Rago, Matthew T DiMare, GiNell Elliott, et al.
Molecular Cancer Research : MCR|March 12, 2021
RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell ProliferationMatthew S Crowe, Tatiana Zavorotinskaya, Charles F Voliva, et al.
Cancer Discovery|February 13, 2015
FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal TumorsFang Li, Hung Huynh, Xiaoyan Li, et al.
Molecular Cancer Therapeutics|September 19, 2019
Distinct Transcriptional Programming Drive Response to MAPK Inhibition in <i>BRAF</i> <sup>V600</sup>-Mutant Melanoma Patient-Derived XenograftsTianshu Feng, Javad Golji, Ailing Li, et al.
Molecular Cancer Research : MCR|September 12, 2018
Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant MelanomaGrace P Leung, Tianshu Feng, Frederic D Sigoillot, et al.
Molecular Cancer Research : MCR|June 29, 2017
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic ActivityCaroline M Emery, Kelli-Ann Monaco, Ping Wang, et al.
The Journal of Clinical Investigation|June 18, 2024
Dysfunction of infiltrating cytotoxic CD8+ T cells within the graft promotes murine kidney allotransplant toleranceTakahiro Yokose, Edward S Szuter, Ivy Rosales, et al.
Elife|April 21, 2017
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human <i>ALK</i> mutant neuroblastoma cell lines and xenograft modelsHui Qin Wang, Ensar Halilovic, Xiaoyan Li, et al.
Cancer Research|June 24, 2011
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patientsRalph Tiedt, Elisa Degenkolbe, Pascal Furet, et al.
Pageof 4